
Abbvie Inc
NYSE:ABBV

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
152.1567
216.66
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
ABBV
stock under the Base Case scenario is
153.25
USD.
Compared to the current market price of 172.99 USD,
Abbvie Inc
is
Overvalued by 11%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Abbvie Inc
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.

Valuation History
Historical valuation for ABBV cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:

With Humira’s patent protection expiring in key markets, AbbVie faces an impending revenue cliff that may be difficult to replace with newer therapies in the short term, potentially straining cash flows and earnings.
AbbVie’s heavy reliance on the immunology franchise means that any pipeline setbacks—especially for Skyrizi or Rinvoq—could undercut management’s guidance for replacing lost Humira sales, exposing the firm to volatility.
The large debt load from recent acquisitions, combined with integration risks from Allergan, may limit AbbVie’s flexibility to pursue additional M&A deals or invest aggressively in R&D, weakening its competitive stance.
Skyrizi and Rinvoq have shown strong clinical data and commercial traction, signifying AbbVie’s potential to sustain leadership in immunology and mitigate the Humira patent cliff through these next-generation therapies.
The Allergan acquisition diversifies AbbVie’s product portfolio into aesthetics and neuroscience, mitigating overdependence on immunology and providing additional long-term growth and cash flow opportunities.
AbbVie’s robust R&D engine and track record of successful drug development, paired with strategic partnerships, position it to expand its oncology and neuroscience pipelines, potentially unlocking future blockbusters beyond its immunology foundation.

Revenue & Expenses Breakdown
Abbvie Inc
Balance Sheet Decomposition
Abbvie Inc
Current Assets | 25.6B |
Cash & Short-Term Investments | 5.6B |
Receivables | 10.9B |
Other Current Assets | 9.1B |
Non-Current Assets | 109.6B |
Long-Term Investments | 279m |
PP&E | 5.1B |
Intangibles | 95B |
Other Non-Current Assets | 9.1B |
Current Liabilities | 38.7B |
Accounts Payable | 31.9B |
Other Current Liabilities | 6.8B |
Non-Current Liabilities | 93.1B |
Long-Term Debt | 60.3B |
Other Non-Current Liabilities | 32.7B |
Free Cash Flow Analysis
Abbvie Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Abbvie Inc
Revenue
|
56.3B
USD
|
Cost of Revenue
|
-16.9B
USD
|
Gross Profit
|
39.4B
USD
|
Operating Expenses
|
-22.9B
USD
|
Operating Income
|
16.5B
USD
|
Other Expenses
|
-12.3B
USD
|
Net Income
|
4.2B
USD
|
ABBV Profitability Score
Profitability Due Diligence
Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

Score
Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.
ABBV Solvency Score
Solvency Due Diligence
Abbvie Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.

Score
Abbvie Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABBV Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for
ABBV
is 219.74 USD
with a low forecast of 174.73 USD and a high forecast of 263.55 USD.
Dividends
Current shareholder yield for ABBV is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ABBV
stock under the Base Case scenario is
153.25
USD.
Compared to the current market price of 172.99 USD,
Abbvie Inc
is
Overvalued by 11%.